3-(7-hydrazinyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-(7-hydrazinyl-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
• 化学式: C₁₃H₁₄N₄O₃
• 分子量: 274.28
• InChiKey: BYYVJTZMRMUAPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
  申请人：Treston Anthony

  公开号：US20070105903A1

  公开（公告）日：2007-05-10

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

  本发明涉及一组有效抑制血管生成的化合物。更具体地说，已经证明氮取代硫酰胺酰亚胺类似物和二取代硫酰胺酰亚胺类似物能够抑制血管生成。重要的是，这些化合物可以口服给药。
• [EN] METHOD FOR PREPARING LENALIDOMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DE LÉNALIDOMIDE<br/>[ZH] 制备来那度胺衍生物的方法
  申请人：UNIV SHANGHAI TECH

  公开号：WO2019242625A1

  公开（公告）日：2019-12-26

  提供了一种制备式(I)化合物的方法，所述方法包括：式(II)化合物的氨基与式(III)化合物在有机碱存在下发生氨基烷基化反应，选择性得到式(I)化合物。还提供了式(I)化合物。
• MDM2 PROTEIN DEGRADERS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20220411432A1

  公开（公告）日：2022-12-29

  The present disclosure provides compounds represented by Formula I-A: A 1 -L 1 -B 1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A 1 , B 1 , and L 1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
• [EN] SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE DÉGRADATION/INTERRUPTION DE SÉRINE THRÉONINE KINASE (AKT) ET PROCÉDÉS D'UTILISATION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2019173516A1

  公开（公告）日：2019-09-12

  Disclosed herein are serine threonine kinase (AKT) degradation / disruption compounds including an AKT ligand, a degradation / disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.